Production (Stage)
RAMM Pharma Corp.
RAMM
CNSX
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -13.41% | -8.23% | -15.08% | -13.61% | -2.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -13.41% | -8.23% | -15.08% | -13.61% | -2.75% |
| Cost of Revenue | -42.08% | -40.93% | -45.13% | -1.32% | 13.90% |
| Gross Profit | 414.75% | 448.95% | 309.00% | -54.40% | -69.43% |
| SG&A Expenses | 23.33% | 45.35% | 42.50% | -17.72% | -13.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -16.19% | -18.12% | -16.96% | -- | 6,853.33% |
| Total Operating Expenses | -1.22% | 11.70% | 8.33% | -11.60% | -4.17% |
| Operating Income | -6.67% | -25.44% | -25.09% | 10.24% | 5.07% |
| Income Before Tax | -51.76% | -81.39% | -112.23% | 57.12% | 57.08% |
| Income Tax Expenses | 28.17% | -901.41% | -16.90% | 12.70% | 12.70% |
| Earnings from Continuing Operations | -51.73% | -80.26% | -112.07% | 57.09% | 57.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.73% | -80.26% | -112.07% | 57.09% | 57.05% |
| EBIT | -6.67% | -25.44% | -25.09% | 10.24% | 5.07% |
| EBITDA | -13.28% | -36.57% | -33.86% | 6.85% | 2.12% |
| EPS Basic | -51.63% | -80.62% | -113.47% | 56.05% | 56.02% |
| Normalized Basic EPS | -2.55% | -29.48% | -35.43% | -3.03% | -1.86% |
| EPS Diluted | -51.63% | -80.62% | -113.47% | 56.05% | 56.02% |
| Normalized Diluted EPS | -2.55% | -29.48% | -35.43% | -3.03% | -1.86% |
| Average Basic Shares Outstanding | -0.26% | -0.76% | -1.36% | -1.98% | -2.10% |
| Average Diluted Shares Outstanding | -0.26% | -0.76% | -1.36% | -1.98% | -2.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |